This is a repository copy of *Treatment response mapping to quantify regional ventilation changes in the lung using hyperpolarized gas MRI*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/114182/

Version: Accepted Version

**Article:**
Horn, F.C., Marshall, H., Collier, G.J. et al. (5 more authors) (2017) Treatment response mapping to quantify regional ventilation changes in the lung using hyperpolarized gas MRI. Radiology, 284 (3). pp. 854-861. ISSN 0033-8419

https://doi.org/10.1148/radiol.2017160532

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Regional Ventilation Changes in the Lung: Treatment Response Mapping by Using Hyperpolarized Gas MR Imaging as a Quantitative Biomarker

Felix C. Horn, PhD
Helen Marshall, PhD
Guilhem J. Collier, PhD
Richard Kay, PhD
Salman Siddiqui, PhD
Christopher E. Brightling, PhD
Juan Parra-Robles, PhD
Jim M. Wild, PhD

Purpose:
To assess the magnitude of regional response to respiratory therapeutic agents in the lungs by using treatment response mapping (TRM) with hyperpolarized gas magnetic resonance (MR) imaging. TRM was used to quantify regional physiologic response in adults with asthma who underwent a bronchodilator challenge.

Materials and Methods:
This study was approved by the national research ethics committee and was performed with informed consent. Imaging was performed in 20 adult patients with asthma by using hyperpolarized helium 3 (3He) ventilation MR imaging. Two sets of baseline images were acquired before inhalation of a bronchodilating agent (salbutamol 400 μg), and one set was acquired after. All images were registered for voxelwise comparison. Regional treatment response, $\Delta R(r)$, was calculated as the difference in regional gas distribution ($R[r] = \text{ratio of inhaled gas to total volume of a voxel when normalized for lung inflation volume}$) before and after intervention. A voxelwise activation threshold from the variability of the baseline images was applied to $\Delta R(r)$ maps. The summed global treatment response map ($\Delta R_{\text{net}}$) was then used as a global lung index for comparison with metrics of bronchodilator response measured by using spirometry and the global imaging metric percentage ventilated volume (%VV).

Results:
$\Delta R_{\text{net}}$ showed significant correlation ($P < .01$) with changes in forced expiratory volume in 1 second ($r = 0.70$), forced vital capacity ($r = 0.84$), and %VV ($r = 0.56$). A significant ($P < .01$) positive treatment effect was detected with all metrics; however, $\Delta R_{\text{net}}$ showed a lower intersubject coefficient of variation (64%) than all of the other tests (coefficient of variation, ≥99%).

Conclusion:
TRM provides regional quantitative information on changes in inhaled gas ventilation in response to therapy. This method could be used as a sensitive regional outcome metric for novel respiratory interventions.

©RSNA, 2017

Online supplemental material is available for this article.
Lung function tests such as spirometry are widely used to clinically assess airflow obstruction and its reversibility, and indexes such as forced expiratory volume in 1 second (FEV₁) are commonly accepted outcome measures in the assessment of therapies for obstructive lung disease. These techniques, while established in respiratory medicine, assess the lungs as one unit, with limited sensitivity to regional ventilation changes (1). Imaging as a diagnostic tool can provide regional insight into alterations of both the structure and the function of the lungs and is increasingly being used as an outcome measure in the early-phase evaluation of respiratory therapeutic agents (2). In particular, regionally specific therapies, such as bronchial thermoplasty in asthma (3), endobronchial valve therapy (4), and lung volume reduction surgery in chronic obstructive pulmonary disease (5), require that regional information be obtained so that the efficacy of the intervention can be assessed. Previous studies have used computed tomography (CT)- and computational fluid dynamics–derived markers of airflow to assess functional changes after bronchodilator therapy (6). However, those methods rely solely on models of ventilation inferred from structural CT images acquired at different levels of inspiration and the repeated use of ionizing radiation, which could be detrimental, particularly in pediatric cohorts.

Functional lung imaging with hyperpolarized gas magnetic resonance (MR) imaging provides three-dimensional (3D) images of lung ventilation in a short breath hold. Hyperpolarized helium 3 (³He) MR imaging has been shown to be a sensitive measure of ventilation heterogeneity in asthma (7,8). Although numerous metrics have been derived to describe ventilation heterogeneity from both hyperpolarized xenon 129 (¹²⁹Xe) and ³He images by using texture-based methods like feature analysis or clustering methods such as k-means clustering (9–12), efforts have been focused on cross-sectional assessment of cohorts. Longitudinal studies and therapy assessment have focused on global outcome measures from hyperpolarized ³He imaging, in particular percentage ventilated volume (%VV) or its counterpart, percentage defect volume (7,13). Although %VV has been shown to correlate with spirometric findings in asthma (14,15), the method is limited by the binary classification of ventilated versus nonventilated lung regions, sacrificing much of the richness of the regional information on lung ventilation heterogeneity present in the images. There is therefore a need for imaging metrics that fully explore the regional sensitivity of these high-resolution images of lung function to assess the success of intervention.

In this study, treatment response mapping (TRM) is introduced as a novel technique to provide regional quantitative information on changes in lung ventilation in response to therapy and is demonstrated in an asthma cohort by measuring bronchodilator response.

### Materials and Methods

The study was approved by the national research ethics committee, and written patient consent was obtained. All data were acquired between February 2012 and June 2013, and the study was funded in parts by Novartis. One author (R.K.) was an employee of Novartis. The authors not employed by Novartis had full control of the data and of the information submitted for publication.

### Study Population and Design

Twenty patients (10 women, 10 men) with a diagnosis of moderate-to-severe asthma (Global Initiative for Asthma step 2–5 [16]) were examined in this retrospective analysis. Patient age range was 21–73 years. Patients were tested for response to a bronchodilator (400 µg salbutamol) with hyperpolarized gas ventilation MR imaging and with spirometry. Patient demographic data and results of pulmonary function tests are shown in Table 1.

### Advances in Knowledge

- Treatment response mapping (TRM) is a novel technique for quantitative assessment of regional lung ventilation changes in response to treatment.
- The net treatment response map integrated over the whole lungs ($\Delta R_{net}$) correlates with changes in spirometry (Pearson correlation: $r = 0.70$ for change in forced expiratory volume in 1 second; $r = 0.84$ for change in forced vital capacity; $P < .01$).
- Compared with standard clinical outcome measures based on lung function, TRM adds information about the size and direction of the regional physiologic response of the lungs.

### Implications for Patient Care

- TRM has potential for the assessment of regional lung interventions such as anti-inflammatory therapies or targeted therapies such as thermoplasty, endobronchial valve therapy, and lung volume reduction surgery.
- Potential clinical applications for TRM are pediatric and longitudinal studies of lung disease progression because patients are not exposed to ionizing radiation.
MR Imaging Data Acquisition
Prior to the imaging acquisition visit, participants refrained from using any short-acting bronchodilators for at least 6 hours. Patients were then imaged in a supine position with a clinical 1.5-T MR imaging unit (HDx; GE Healthcare, Milwaukee, Wis) with a dedicated MR ³He RF coil. Hydrogen 1 MR imaging was performed with the system’s body coil. Each image was acquired on inhalation of 1 L of gas from a Tedlar bag (350 mL hyperpolarized ³He mixed with 650 mL N₂) from functional residual capacity. Prior to imaging, patients were trained in the breathing maneuver. Three ventilation MR imaging acquisitions were performed in separate breath holds; two at baseline within 5 minutes of each other, then an additional acquisition 20 minutes after bronchodilator administration to assess short-term airway responsiveness (19) (Fig 1). Each breath-hold acquisition consisted of (a) functional images (hyperpolarized ³He ventilation; resolution, 3 × 3 × 10 mm; duration, 9 seconds) and (b) structural images (¹H anatomy; resolution, 3 × 6 × 10 mm; duration, 4 seconds). To switch between ³He and ¹H MR imaging, the imaging unit required approximately 3–5 seconds, leading to a total breath-hold duration of less than 18 seconds in all cases. Because both functional and structural images are acquired back-to-back during a single breath hold, they are intrinsically coregistered (20).

Image Processing Algorithm for TRM
Structural proton images were first registered between the different time points, and the resulting transformation was applied to the same breath-hold ³He ventilation images (21). This avoided the registration of the ³He ventilation images being influenced by regional changes in gas distribution between acquisitions (Appendix E1 [online]). Then, images were segmented to extract the ventilated lung volume by using ScanIP (Simpleware, Exeter, England).

Regional ventilation was then calculated from the image intensity for each data set. Ventilation as regional gas distribution in the lung is quantified by conversion of image intensity to the volume fraction occupied by the inhaled tracer gas in each voxel. This requires knowledge of voxel volume (Vvoxel) and inhaled gas volume (Vbag), as described by Tzeng et al (10):

\[
R'(r) = \frac{I(r)}{V_{\text{voxel}}} \frac{V_{\text{bag}}}{I_{\text{tot}}}
\]

where I(r) is the regional image intensity at position r(x,y,z), I_{\text{tot}} is the integrated image intensity of all ventilated areas in the image, and R'(r) is the resulting regional gas volume fraction in each voxel. For example, in the trachea directly after inhalation, the gas composition is usually the same as that inhaled from the bag, and hence R' = 1.

To compare R'(r) between data sets, the differences in gas dilution of the tracer gas in the ventilated airspaces have to be taken into account.

---

**Table 1**
Overview of Demographics and Results of Pulmonary Function Tests in 20 Patients with Asthma

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>51 ± 12</td>
</tr>
<tr>
<td>Female: male ratio</td>
<td>10:10</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.66 ± 0.07</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>82 ± 15</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30 ± 5</td>
</tr>
<tr>
<td>GINA classification</td>
<td>4.10 ± 0.68</td>
</tr>
<tr>
<td>No. of pack-years</td>
<td>0.62 ± 1.91</td>
</tr>
<tr>
<td>RV (L)</td>
<td>2.78 ± 1.18</td>
</tr>
<tr>
<td>TLC (L)</td>
<td>6.23 ± 1.54</td>
</tr>
<tr>
<td>FEV₁ (percentage predicted)</td>
<td>71 ± 28 (27–122)</td>
</tr>
<tr>
<td>FVC (percentage predicted)</td>
<td>92 ± 22 (54–138)</td>
</tr>
<tr>
<td>FEV₁/FVC (percentage predicted)</td>
<td>75 ± 17 (31–83)</td>
</tr>
</tbody>
</table>

Note.—Unless otherwise specified, all data are means ± standard deviations, with ranges in parentheses. All measurements were obtained before application of the bronchodilator. Spirometry was performed with a rolling seal Vitalograph spirometer (Vitalograph, Buckingham, England) according to guidelines (17). BMI = body mass index, FVC = forced vital capacity, GINA = Global Initiative for Asthma (16), pack-years = lifetime tobacco exposure (1 pack-year was defined as 20 cigarettes a day for a year), RV = residual volume, TLC = total lung capacity. Predicted values were calculated by using equations (18).

---

**Figure 1:** Image processing workflow from left to right: 3D image sets (proton and hyperpolarized gas ventilation image within a single breath hold) are acquired twice at baseline to calculate baseline variability. Twenty minutes after bronchodilator application, another 3D set is acquired. The differences between pre- and post-bronchodilator images are plotted as treatment response ΔR(r) maps and are compared with a regional treatment activation threshold from baseline variability, ΔR(r)′. This data set was obtained in a 54-year-old man (patient 2).
After intervention, airway opening and closure will likely result in differences in ventilated lung volume. These variations can cause dilution of the tracer gas concentration when it is inhaled in the same dose from breath to breath. The ventilated lung volume after treatment \( V_{LTx} \) was chosen as the reference point, and the normalized gas volume fraction \( R \) was computed as follows:

\[
R = R' \cdot \frac{V}{V_{LTx}}. \tag{2}
\]

where \( V \) is the ventilated lung volume calculated from the image of interest. Equation (2) assumes that regional gas concentration scales uniformly with lung volume changes across all voxels in the lungs.

The difference in gas volume fraction, \( \Delta R(r) \), before and after intervention is then calculated for all positions \( r \) to quantify the treatment response map. \( \Delta R(r) \) is, in effect, the regionally measured redistribution of the gas mixture when inhaling identical doses before and after intervention. Like \( R \), the treatment response map \( \Delta R(r) \) is a gas volume fraction, which measures the size and direction of ventilation change due to intervention. The major airways were excluded, as they do not contribute to gas exchange and can be expected to be fully ventilated in each breath. To account for ventilation changes related to physiologic baseline variability from acquisition to acquisition, a voxelwise baseline variability map, \( \Delta R_b(r) \), was calculated as the standard deviation of the differences in gas volume fraction \( R(r) \) between the two (filtered) baseline acquisitions. \( \Delta R(r) \) is set to zero (no effect) for voxels whose \( \Delta R(r) = -\Delta R_b(r) \), and is displayed as white voxels. For remaining voxels, a positive \( \Delta R(r) \) (improvement in local ventilation) is shown with a green color scale, and a negative \( \Delta R(r) \) (reduction in local ventilation) is shown with a red color scale. In addition, a global value for net treatment response over the whole lungs, \( \Delta R_{net} \), was calculated as follows:

\[
\Delta R_{net} = \sum_r \Delta R(r) \cdot V_{voxel}. \tag{3}
\]

\( \Delta R_{net} \) is summed over the lung volume and can be expressed as the percentage of the inhaled gas mix (1 L) or, alternatively, in milliliters, as the volume of the gas dose that is delivered to newly ventilated regions of the lung after inhalation of a 1-L dose. We emphasize that expression of \( \Delta R_{net} \) in milliliters is not to be confused with the volume of the lungs that opens up in response to the bronchodilator; instead, it is the amount of the tracer gas (from a 1-L total inhaled dose), that reaches newly ventilated lungs. For an inhaled gas mix of 1 L, a theoretical redistribution of \( \Delta R_{net} = 100\% \) or +1 liter would therefore mean a complete redistribution of all inhaled gas in previously non- or little-ventilated regions. The metric quantifies the sum of regional gas redistribution as result of the same dose inhaled before and after an intervention.

Accordingly, the global positive and negative change can be calculated by taking only positive or negative \( \Delta R(r) \) into account. An analysis of error propagation related to these steps of performing TRM is presented in Appendix E1 (online).

### Table 2

**Summary of Outcome Measures Used to Assess Treatment Response, Including \( \Delta R_{net} \)**

**A: Absolute Measurements**

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Before Bronchodilator</th>
<th>After Bronchodilator</th>
<th>( P )-Value</th>
<th>Difference (before vs after Bronchodilator)</th>
<th>95% CI of Median</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV(_1), (percentage predicted)</td>
<td>72 (44–96)</td>
<td>79 (58–100)</td>
<td>0.002</td>
<td>6.3 (4.5–13)</td>
<td>5.1, 12</td>
<td>99</td>
</tr>
<tr>
<td>FVC (percentage predicted)</td>
<td>85 (76–110)</td>
<td>93 (85–120)</td>
<td>0.04</td>
<td>5.2 (1.9–8.3)</td>
<td>2.8, 8.0</td>
<td>137</td>
</tr>
<tr>
<td>FEV/FVC (%)</td>
<td>68 (48–73)</td>
<td>88 (65–91)</td>
<td>&lt;0.001</td>
<td>3.6 (2.4–5.5)</td>
<td>2.7, 5.2</td>
<td>143</td>
</tr>
<tr>
<td>%VVT at imaging</td>
<td>88 (83–94)</td>
<td>93 (90–97)</td>
<td>0.009*</td>
<td>3.5 (0.2–5.7)</td>
<td>0.41, 5.4</td>
<td>109</td>
</tr>
</tbody>
</table>

**B: Differential Measurements**

<table>
<thead>
<tr>
<th>Outcome Metric</th>
<th>Positive ( \Delta R_{net} )</th>
<th>Negative ( \Delta R_{net} )</th>
<th>( P )-Value</th>
<th>( \Delta R_{net} )</th>
<th>95% CI of Median</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \Delta R_{net} ) (%)</td>
<td>20 (16–26)</td>
<td>9 (7–11)</td>
<td>&lt;0.001*</td>
<td>11 (6.6–14)</td>
<td>8.8, 12.4</td>
<td>64</td>
</tr>
<tr>
<td>( \Delta R_{net} ) (mL)</td>
<td>210 (160–260)</td>
<td>92 (71–110)</td>
<td>&lt;0.001*</td>
<td>110 (66–140)</td>
<td>88.2, 123.9</td>
<td>64</td>
</tr>
</tbody>
</table>

Note.—All data are medians, with interquartile ranges (25th–75th quartile) in parentheses. Unless otherwise specified, \( P \)-values were calculated with the paired \( t \)-test. CI = confidence interval. Patient-specific values are shown in Tables E2 and E3 (online) alongside scatterplots in Figure E1 (online).

* CV = coefficient of variation (ratio of standard deviation to mean of treatment effect).

† Non-normally distributed data, so the Wilcoxon signed rank test was used.

### Technical Developments

**Treatment Response Mapping of Regional Ventilation Changes in the Lung**

Horn et al

**After intervention, airway opening and closure will likely result in differences in ventilated lung volume. These variations can cause dilution of the tracer gas concentration when it is inhaled in the same dose from breath to breath. The ventilated lung volume after treatment \( V_{LTx} \) was chosen as the reference point, and the normalized gas volume fraction \( R \) was computed as follows:**

\[
R = R' \cdot \frac{V}{V_{LTx}}. \tag{2}
\]

**where \( V \) is the ventilated lung volume calculated from the image of interest. Equation (2) assumes that regional gas concentration scales uniformly with lung volume changes across all voxels in the lungs.**

**The difference in gas volume fraction, \( \Delta R(r) \), before and after intervention is then calculated for all positions \( r \) to quantify the treatment response map. \( \Delta R(r) \) is, in effect, the regionally measured redistribution of the gas mixture when inhaling identical doses before and after intervention. Like \( R \), the treatment response map \( \Delta R(r) \) is a gas volume fraction, which measures the size and direction of ventilation change due to intervention. The major airways were excluded, as they do not contribute to gas exchange and can be expected to be fully ventilated in each breath. To account for ventilation changes related to physiologic baseline variability from acquisition to acquisition, a voxelwise baseline variability map, \( \Delta R_b(r) \), was calculated as the standard deviation of the differences in gas volume fraction \( R(r) \) between the two (filtered) baseline acquisitions. \( \Delta R(r) \) is set to zero (no effect) for voxels whose \( \Delta R(r) = -\Delta R_b(r) \), and is displayed as white voxels. For remaining voxels, a positive \( \Delta R(r) \) (improvement in local ventilation) is shown with a green color scale, and a negative \( \Delta R(r) \) (reduction in local ventilation) is shown with a red color scale. In addition, a global value for net treatment response over the whole lungs, \( \Delta R_{net} \), was calculated as follows:**

\[
\Delta R_{net} = \sum_r \Delta R(r) \cdot V_{voxel}. \tag{3}
\]

**\( \Delta R_{net} \) is summed over the lung volume and can be expressed as the percentage of the inhaled gas mix (1 L) or, alternatively, in milliliters, as the volume of the gas dose that is delivered to newly ventilated regions of the lung after inhalation of a 1-L dose. We emphasize that expression of \( \Delta R_{net} \) in milliliters is not to be confused with the volume of the lungs that opens up in response to the bronchodilator; instead, it is the amount of the tracer gas (from a 1-L total inhaled dose), that reaches newly ventilated lungs. For an inhaled gas mix of 1 L, a theoretical redistribution of \( \Delta R_{net} = 100\% \) or +1 liter would therefore mean a complete redistribution of all inhaled gas in previously non- or little-ventilated regions. The metric quantifies the sum of regional gas redistribution as result of the same dose inhaled before and after an intervention.**

**Accordingly, the global positive and negative change can be calculated by taking only positive or negative \( \Delta R(r) \) into account. An analysis of error propagation related to these steps of performing TRM is presented in Appendix E1 (online).**

### Percentage Ventilated Volume

**Percentage ventilated volume was calculated as the ratio of lung ventilated volume (from segmented 3He ventilation images) to the total volume of the lung in the thorax (from segmentation of the 3He image), as described previously (20).**

**Spirometry**

Spirometry was performed with a rolling seal spirometer (Vitalograph, Buckingham, England) before and 20 minutes after bronchodilator inhalation according to American Thoracic...
Society/European Respiratory Society guidelines (17). A minimum of three acceptable FVC maneuvers were performed, and the highest FEV₁ and FVC of the acceptable curves were recorded. Percentage predicted values were calculated as previously described (18). All pre-bronchodilator tests were performed after all bronchodilators had been withheld for at least 6 hours.

Statistical Analysis
Statistical analysis was performed by using Prism (GraphPad Software, San Diego, Calif). All data sets were first tested for normality by using a D’Agostino-Pearson omnibus normality test. Significance of treatment effect was tested by using a paired t test or, in the case of a nonnormal distribution, the Wilcoxon signed-rank test. The probability that the null hypothesis (H₀ = no treatment effect is found) can be rejected was tested (for P < .05 H₀ rejected). Values are reported as medians ± interquartile ranges (25th–75th quartiles). Correlations were calculated by using the Pearson r correlation (Spearman correlation in the case of nonnormality), and the correlation coefficient and P value of correlation are reported. P < .05 was considered to indicate a significant difference.

Results
An overview of results from the global MR imaging metrics (ΔRᵣnet, %VV) and lung function test measurements (FEV₁, FVC) is presented in Table 2 (details for each patient are presented in Tables E2 and E3 [online]). TRM indicated an overall positive effect of the bronchodilator, in agreement with other metrics; the P values from paired t testing are shown in Table 2. An average intersubject baseline variability ΔRᵣ of 4.74% ± 4.68 was found. Example ³He ventilation images and the resulting ΔR maps in patient 2 are shown in Figure 2. Three-dimensional renderings of treatment response maps in four more patients are shown in Figure 3. Figure 4 shows correlation of ΔRᵣnet with changes in the other metrics evaluated: %VV (r = 0.56; P = .01), FEV₁ (r = 0.70; P < .01), and FVC (r = 0.84; P < .01). ΔRᵣnet and FEV₁/FVC did not correlate significantly. The intersubject coefficient of variation of ΔRᵣnet was 64%, which is much lower than those of %VV and spirometry (both ≥ 99%). Figure 5 shows the changes as assessed by all
Figure 3: Example 3D-rendered treatment response maps in four volunteers, along with corresponding histograms.

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Patient 5</th>
<th>Patient 8</th>
<th>Patient 10</th>
<th>Patient 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>(gender, age)</td>
<td>(male, 41)</td>
<td>(male, 59)</td>
<td>(female, 62)</td>
<td>(female, 45)</td>
</tr>
<tr>
<td>Baseline FEV₁(% pred.)</td>
<td>69.9</td>
<td>95.2</td>
<td>43.5</td>
<td>71.8</td>
</tr>
<tr>
<td>positive/negative ΔRₙₑₜ [%]</td>
<td>27/7</td>
<td>20/9</td>
<td>33/10</td>
<td>28/7</td>
</tr>
<tr>
<td>ΔRₙₑₜ volume [ml]/[%]</td>
<td>199/20</td>
<td>111/11</td>
<td>227/23</td>
<td>212/21</td>
</tr>
</tbody>
</table>

Figure 4: Graphs show (a) correlation of ΔRₙₑₜ (as a percentage) with changes in %VV from before and after treatment (Δ%VV) (Spearman r = 0.56, P = .01), (b) correlation of ΔRₙₑₜ with changes in FEV₁ from treatment (ΔFEV₁) (Pearson r = 0.70, P = .004), and (c) correlation of ΔRₙₑₜ with FVC (Pearson r = 0.84, P < .001). Dotted lines = 95% confidence intervals.
methods for each patient and their collective median (interquartile range).

Discussion

TRM of changes in lung ventilation in response to therapy is demonstrated here with pre- and post-bronchodilator imaging in a cohort of patients with asthma. The effects of a bronchodilator are typically clinically assessed with spirometry, airway resistance, or static lung volume measurement. Although these methods are quick and easy to repeat, regional changes in lung ventilation and airway opening and closing are not accessible with these methods. This is likely to reduce the sensitivity of these clinical tests to subtle but still clinically important changes in ventilation, in particular when the treatment is focused on a small lung region (e.g., with bronchothermoplasty or endobronchial valves). Imaging as a diagnostic tool can provide regional insight into alterations of both the structure and the function of the lung. Airway wall measurements and models of lobar ventilation change from inspiratory and expiratory computed tomography (CT) have both been proposed as image-based outcome measures in asthma (6), but the repeated exposure to ionizing radiation is an issue. Hyperpolarized gas MR imaging directly measures functional information from the lungs without ionizing radiation, and TRM is a potentially powerful tool for longitudinal and pediatric studies. Previously, oxygen-enhanced MR imaging has been used to measure changes induced by bronchodilators and corticosteroids (22). However, it is unclear to what extent this method captures changes in ventilation, as signal changes are caused by the interaction of protons with $O_2$ dissolved in tissue and blood (23).

Signal intensity from hyperpolarized gas MR images is proportional to the distribution of inhaled tracer gas in the lung and is therefore a direct measure of ventilation. The TRM method demonstrated here uses this relationship to regionally quantify the magnitude of ventilation changes.

The inherent baseline variability of the images from acquisition to acquisition without any intervention is also taken into account in the algorithm and defines a voxelwise threshold for “treatment response.” This is important as it has been previously shown that originally nonventilated regions of the lung can change size and position on the same day in patients with asthma without intervention (13).

One of the most striking findings was the close correlation of FVC and FEV1 with the global TRM metric $\Delta R_{net}$. The fact that imaging and spirometry were not performed on the same day represents a limitation of this study and might explain why the correlations between spirometry and $\Delta R_{net}$ were not stronger. Although all of the tested metrics showed a significant effect from the bronchodilator ($P < .01$), the largest changes were found from $\Delta R_{net}$ (Fig 5). The intersubject coefficient of variation of $\Delta R_{net}$ was also smaller (64%) than for the other metrics (≥99%).

Some improvements in FVC were high (39% for patient 2) and might reflect recruitment of air spaces due to decreased gas trapping, an assumption that is supported by increases in %VV (3.8% for patient 2) in most patients. The weaker correlation ($r = 0.56$) of $\Delta R_{net}$ with changes in %VV supports the assumption that changes in ventilation are not only a result of a net increase in viable ventilated airspace volume but also reflect changes in heterogeneity of the magnitude of the ventilation that are regionally elucidated with the TRM method.

In patients with a limited spirometric response (<12%) to a bronchodilator, TRM effectively distinguishes regions of the lung with an increase in ventilation from regions demonstrating reduced ventilation. This lends some regional evidence to the possibility that bronchodilators are not always effective and can be potentially detrimental in selected regions of the lung in asthma. Similar observations have been reported in other imaging biomarker studies (22). Nevertheless, negative $\Delta R(r)$ can result from two other mechanisms; while a degradation of ventilation is
observed in practice in some lung regions after treatment, other regions of negative $\Delta R(r)$ might result from initially hyperventilated regions of lung that were perhaps compensating for obstruction elsewhere, then returning to more-even levels after bronchodilator application. Understanding the physiologic mechanism and phenotyping these “red regions” of worsened ventilation warrants further investigation.

In conclusion, TRM is able to complement the current techniques for regionally quantifying changes in ventilation in the lungs. The future clinical potential of the method lies in determining the regional response of the lungs to new therapies where established lung function tests do not provide sensitive enough outcome measures. This sensitivity to local changes in ventilation could also result in a reduction of patient cohort numbers required to confirm success of a treatment in a clinical trial.

Current limitations of the technique include the requirement for hyperpolarized gas MR imaging infrastructure for effective delivery in a clinical setting. Recent advances may help overcome this barrier in years to come, as the technique may also be directly applicable to ventilation images acquired by using other gases to image lung function, such as hyperpolarized $^{129}$Xe or fluorine 19 fluorinated gases like perfluoropropane (24,25).

Acknowledgments: The authors acknowledge Professor David Barber and Bilal Tahir for their help with the image registration. The authors acknowledge research administrators Amisha Singapuri and Leanne Armstrong for their help in organizing the study.

Disclosures of Conflicts of Interest: F.C.H. disclosed no relevant relationships. H.M. disclosed no relevant relationships. G.J.C. disclosed no relevant relationships. R.K. Activities related to the present article: is an employee of Novartis Pharmaceuticals. Activities not related to the present article: disclosed no relevant relationships. Other relationships: disclosed no relevant relationships. S.S. disclosed no relevant relationships. C.E.B. disclosed no relevant relationships. J.P. disclosed no relevant relationships. J.M.W. disclosed no relevant relationships.

References
11. He M, Driebeens B, Que LG, Huang YT. Using hyperpolarized (129)Xe MRI to quantify the pulmonary ventilation distribution. Acad Radiol 2016;23(12):1521–1531.